Mikkael Sekeres, MD, chief of the division of hematology at the University of Miami Sylvester Comprehensive Cancer Center, and David Steensma, MD, global hematology head at Novartis, share their recent experiences undergoing career transitions. The physicians dive into a discussion on how often fellowships are given to candidates who are pursuing academic careers, how and why the decisions were made to leave one institution for another (or an institution for industry), whether or not to interview for new positions discreetly, how to approach negotiating aspects of a new employment contract, and so much more.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
